• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Sunpharma Share Price

    Sun Pharmaceutical Industries Share PriceSun Pharmaceutical Industries

    Large Cap 50.4k Result
    ₹1,231.15
    -0.1 (-0.01%)
    As on 05 December, 2023 | 07:18 BSE: 524715 NSE: SUNPHARMAISIN: INE044A01036

    Sun Pharmaceutical Industries Performance

    Day Range

    • Low 1,220.50
    • High 1,240.00
    ₹ 1,231.15

    52 Week Range

    • Low 922.45
    • High 1,241.85
    ₹ 1,231.15
    • Open Price1,237.25
    • Previous Close1,231.25
    • Volume1615837

    Start SIP in Sun Pharmaceutical Industries

    Start SIP

    Sun Pharmaceutical Industries Share Price

    • Over 1 Month 7.89%
    • Over 3 Month 11.02%
    • Over 6 Month 23.16%
    • Over 1 Year 18.38%

    Sun Pharmaceutical Industries Key Statistics

    P/E Ratio 34.6
    PEG Ratio 0.3
    Market Cap Cr 295,394
    Price to Book Ratio 5
    EPS 14
    Dividend 0.9
    Relative Strength Index 73.2
    Money Flow Index 60.17
    MACD Signal 17.69
    Average True Range 18.84

    Sun Pharmaceutical Industries F&O

    Sun Pharmaceutical Industries Futures
    Sun Pharmaceutical Industries Option Chain

    Sun Pharmaceutical Industries Investment Rating

    • Master Rating:

    • Sun Pharm.Industries has an operating revenue of Rs. 46,304.89 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 21% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 16% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Sun Pharmaceutical Industries Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 5,0964,3835,8014,5505,2854,8623,988
    Operating Expenses Qtr Cr 3,7103,5173,5883,6463,6223,4833,007
    Operating Profit Qtr Cr 1,3869492,3619991,6631,4501,000
    Depreciation Qtr Cr 393415412430384375354
    Interest Qtr Cr 194158161131938791
    Tax Qtr Cr 189-9191525486
    Net Profit Qtr Cr 889381-1,0214871,2131,012-1,286
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 21,09116,544
    Operating Expenses Annual Cr 14,33912,678
    Operating Profit Annual in Cr 6,4732,908
    Depreciation Cr 1,6011,350
    Interest Annual Cr 472388
    Tax Annual Cr 50407
    Net Profit Annual Cr 1,691-100
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 5077,636
    Cash from Investing Activity Annual Cr -705-2,702
    Cash from Financing Annual Activity Cr 169-4,871
    Net Cash Flow Annual Cr -2963
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 23,74824,588
    Fixed Assets Annual Cr 9,56510,541
    Total Non Current Assets Annual Cr 24,52231,062
    Total Current Assets Annual Cr 16,4659,704
    Total Assets Annual Cr 40,98740,765
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 99102
    ROE Annual % 70
    ROCE Annual % 168
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3225
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 12,19211,78510,72611,10010,95210,6449,386
    Operating Expenses Qtr Cr 9,0138,6098,1298,2377,9967,8777,106
    Operating Profit Qtr Cr 3,1793,3322,8023,0042,9572,8842,340
    Depreciation Qtr Cr 633651672660610588556
    Interest Qtr Cr 49819346191437
    Tax Qtr Cr 390468223283152189147
    Net Profit Qtr Cr 2,3762,0231,9842,1662,2622,061-2,277
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 44,52039,576
    Operating Expenses Annual Cr 32,23928,257
    Operating Profit Annual in Cr 11,64710,398
    Depreciation Cr 2,5292,144
    Interest Annual Cr 172127
    Tax Annual Cr 8481,076
    Net Profit Annual Cr 8,4743,273
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 4,9598,985
    Cash from Investing Activity Annual Cr -7,944-5,725
    Cash from Financing Annual Activity Cr 2,376-5,193
    Net Cash Flow Annual Cr -608-1,934
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 55,99548,011
    Fixed Assets Annual Cr 20,68117,197
    Total Non Current Assets Annual Cr 40,86034,785
    Total Current Assets Annual Cr 39,88335,015
    Total Assets Annual Cr 80,74469,800
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 247213
    ROE Annual % 157
    ROCE Annual % 1617
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2829
    Invest in Sun Pharmaceutical Industries

    Sun Pharmaceutical Industries Technicals

    EMA & SMA

    Current Price
    ₹1,231.15
    -0.1 (-0.01%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,192.15
    • 50 Day
    • ₹1,163.55
    • 100 Day
    • ₹1,131.20
    • 200 Day
    • ₹1,082.14
    • 20 Day
    • ₹1,192.31
    • 50 Day
    • ₹1,154.64
    • 100 Day
    • ₹1,138.98
    • 200 Day
    • ₹1,060.47

    Sun Pharmaceutical Industries Resistance and Support

    PIVOT
    ₹1,230.55
    Resistance
    First Resistance 1,240.60
    Second Resistance 1,250.05
    Third Resistance 1,260.10
    RSI 73.20
    MFI 60.17
    MACD Single Line 17.69
    MACD 20.76
    Support
    First Resistance 1,221.10
    Second Resistance 1,211.05
    Third Resistance 1,201.60

    Sun Pharmaceutical Industries Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,645,745 100,637,307 61.15
    Week 2,235,382 139,644,301 62.47
    1 Month 1,615,142 95,277,197 58.99
    6 Month 2,295,142 136,882,272 59.64

    Sun Pharmaceutical Industries Result Highlights

    Sun Pharmaceutical Industries Synopsis

    NSE-Medical-Generic Drugs

    Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 20812.14 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2023. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.
    Market Cap 295,394
    Sales 20,156
    Shares in Float 110.37
    No of funds 1048
    Yield 0.93
    Book Value 12.43
    U/D Vol ratio 1.2
    LTDebt / Equity 32
    Alpha 0.07
    Beta 0.38

    Sun Pharmaceutical Industries

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 54.48%54.48%54.48%54.48%
    Mutual Funds 13.07%13.16%12.91%12.46%
    Insurance Companies 5.06%5.12%5.12%5.55%
    Foreign Portfolio Investors 16.78%16.48%16.88%16.87%
    Financial Institutions/ Banks 0.04%0.08%0.08%0.04%
    Individual Investors 5.55%5.65%5.7%5.76%
    Others 5.02%5.03%4.83%4.84%

    Sun Pharmaceutical Industries Management

    Name Designation
    Mr. Dilip S Shanghvi Managing Director
    Mr. Sailesh T Desai Whole Time Director
    Mr. Sudhir V Valia Non Exe.Non Ind.Director
    Dr. Pawan Goenka Independent Director
    Mr. Rama Bijapurkar Independent Director
    Mr. Gautam Doshi Independent Director
    Mr. Aalok D Shanghvi Whole Time Director
    Mr. Sanjay Asher Independent Director
    Mr. Rolf Hoffmann Independent Director

    Sun Pharmaceutical Industries Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Sun Pharmaceutical Industries Corporate Action

    Date Purpose Remarks
    2023-11-01 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-26 Audited Results & Final Dividend
    2023-01-31 Quarterly Results & Interim Dividend
    2022-11-01 Quarterly Results
    Date Purpose Remarks
    2023-07-28 FINAL Rs.4.00 per share(400%)Final Dividend
    2023-02-08 INTERIM Rs.7.50 per share(750%)Interim Dividend
    2022-08-22 FINAL Rs.3.00 per share(300%)Final Dividend
    2022-02-10 INTERIM Rs.7.00 per share(700%)Interim Dividend
    2021-02-10 INTERIM Rs.5.50 per share(550%)Interim Dividend

    Sun Pharmaceutical Industries MF Shareholding

    Name Amount(cr)
    SBI Nifty 50 ETF 155,471
    SBI S&P BSE Sensex ETF 95,207
    HDFC Balanced Advantage Fund Growth 63,981
    ICICI Prudential Balanced Advantage Fund Growth 49,871
    UTI Nifty 50 Exchange Traded Fund 42,363

    Sun Pharmaceutical Industries FAQs

    What is Share Price of Sun Pharmaceutical Industries ?

    Sun Pharmaceutical Industries share price is ₹1,231 As on 05 December, 2023 | 07:04

    What is the Market Cap of Sun Pharmaceutical Industries ?

    The Market Cap of Sun Pharmaceutical Industries is ₹295394.1 Cr As on 05 December, 2023 | 07:04

    What is the P/E ratio of Sun Pharmaceutical Industries ?

    The P/E ratio of Sun Pharmaceutical Industries is 34.6 As on 05 December, 2023 | 07:04

    What is the PB ratio of Sun Pharmaceutical Industries ?

    The PB ratio of Sun Pharmaceutical Industries is 5 As on 05 December, 2023 | 07:04

    What is the future of Sun Pharmaceutical Industries (Sun Pharma)?

    Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD

    Who is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma)?

    Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).

    What is the ROE of Sun Pharmaceutical Industries (Sun Pharma)?

    The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.

    Is Sun Pharmaceutical Industries (Sun Pharma) Debt to Equity Ratio?

    Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.

    What is the PE ratio of Sun Pharmaceutical Industries (Sun Pharma)?

    The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.